Real world experience with Besremi in ET and PV following exposure to Pegasys.

[Manouche]

Abstract

Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy »

sciencedirect.com/science/a...

[EPguy]

Thanks for the new info. This is the full article:

ncbi.nlm.nih.gov/pmc/articl...

Seems they had hard to treat pts. In some PV's Besremi worked better than PEG, but low PEG response in ET predicted poor Bes response.

A highlight: "Interestingly, the dose of ropegIFN in the patient with CHR was lower compared to doses reported in trials" They seem surprised but many here know this well.

and : "We have additionally reported on a successful case of ropegIFN use during pregnancy"

Very small sample.

[PhysAssist]

Hi Manouche, and thanks!

Here is the PDF link for the full-text to download:

sciencedirect.com/science/a...